HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease

The candidate prostate cancer susceptibility gene HPC2/ELAC2 has two common coding polymorphisms: (Ser→Leu 217) and (Ala→Thr 541). The Thr541 variant in the HPC2/ELAC2 gene has previously been reported to be at an increased frequency in prostate cancer cases. To evaluate this hypothesis we genotyped...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2002-10, Vol.87 (8), p.905-908
Main Authors: Meitz, J C, Edwards, S M, Easton, D F, Murkin, A, Ardern-Jones, A, Jackson, R A, Williams, S, Dearnaley, D P, Stratton, M R, Houlston, R S, Eeles, R A
Format: Article
Language:English
Subjects:
Adult
Age of Onset
Aged
Aged, 80 and over
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Cancer Research
Case-Control Studies
DNA - blood
DNA - genetics
DNA, Neoplasm - metabolism
Drug Resistance
Epidemiology
Female
Genetic Predisposition to Disease - genetics
Genetic Variation - genetics
Genetics and Genomics
Genotype
Humans
Male
Medical sciences
Middle Aged
Molecular Medicine
Mutation - genetics
Neoplasm Proteins - genetics
Nephrology. Urinary tract diseases
Odds Ratio
Oncology
Polymorphism, Genetic
Prostatic Neoplasms - genetics
Prostatic Neoplasms - pathology
Risk Factors
Tumors of the urinary system
Urinary tract. Prostate gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The candidate prostate cancer susceptibility gene HPC2/ELAC2 has two common coding polymorphisms: (Ser→Leu 217) and (Ala→Thr 541). The Thr541 variant in the HPC2/ELAC2 gene has previously been reported to be at an increased frequency in prostate cancer cases. To evaluate this hypothesis we genotyped 432 prostate cancer patients (including 262 patients diagnosed ⩽55 years) and 469 UK, population based control individuals with no family history of cancer. We found no significant difference in the frequencies of Thr541‐containing genotypes between cases and controls (OR=1.41, 95% CI 0.79–2.50). The association remained non-significant when the analysis was restricted to cases divided by age of onset into those diagnosed ⩽55 years (OR=1.50, 95% CI 0.79–2.85) or to patients diagnosed >55 years (OR=1.27, 95% CI 0.59–2.74). We conclude that any association between the Thr541 variant and prostate cancer is likely to be weak.
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6600564